MedTrace Logo

Genome-wide Analysis of Lipid-lowering Efficacy and Drug Level of Simvastatin and Rosuvastatin

NCT04921657 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 362

Last updated 2021-09-02

No results posted yet for this study

Summary

This study will perform a genome-wide association study (GWAS) of the lipid responses to rosuvastatin and simvastatin and plasma concentrations of these two statins in a homogeneous group of Han Chinese patients.

Conditions

Interventions

DRUG

Rosuvastatin 10mg

Sponsors & Collaborators

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • BRIAN TOMLINSON, MD · Chinese University of Hong Kong

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2021-08-31
Completion
2021-08-31
FDA Drug
Yes

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04921657 on ClinicalTrials.gov